These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27479731)

  • 1. Erratum to: Nguyen PL. Rethinking the Balance of Risk and Benefit of Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2016;94:975-977.
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1549. PubMed ID: 27479731
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350).
    Oton CA
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):291-2; author reply 292. PubMed ID: 15850937
    [No Abstract]   [Full Text] [Related]  

  • 3. Erratum to: Tward, J; Lenz, L; Flake II, DD; Rajamani, S; Yonover, P; Olsson, C; Kapoor, DA; Mantz, C; Liauw, SL; Antic, T; Fabrizio, M; Salzstein, D; Shore, N; Albertson, D; Henderson, J; Lee, SP; Gay, HA; Michalski, J; Hung, A; Raben, D; Garraway, I; Lewis, MS; Nguyen, PL; Marshall, DT; Brawer, MK; Stone, S; Cohen, T. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys 2022;113:66-76. doi.org/10.1016/j.ijrobp.2021.09.034.
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):543. PubMed ID: 36621237
    [No Abstract]   [Full Text] [Related]  

  • 4. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009).
    Roach M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):316; author reply 316. PubMed ID: 19695446
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727).
    Dal Pra A; Milosevic M; Hill R; Wouters B; Warde P; Bristow RG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1319. PubMed ID: 22385713
    [No Abstract]   [Full Text] [Related]  

  • 6. Erratum to: Kong X-T, Nguyen NT, Choi YJ, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys 2018;100:1195-1203.
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1289. PubMed ID: 30900570
    [No Abstract]   [Full Text] [Related]  

  • 7. In regards to Dr. Glatstein Int J Radiat Oncol Biol Phys 2003;55:561-562, and Dr. Amols, Int J Radiat Oncol Biol Phys 2003;56:1507.
    Nutting C; Harrington K
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1316-7; author reply 1317. PubMed ID: 15001278
    [No Abstract]   [Full Text] [Related]  

  • 8. Lung V20 measurements: In regard to Seppenwoolde et al. (Int J Radiat Oncol Biol Phys 2003;55:724-735), and Tsujino et al. (Int J Radiat Oncol Biol Phys 2003;56:1208-1209).
    Garces YI; Miller RC
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1636; author reply 1636-7. PubMed ID: 15050346
    [No Abstract]   [Full Text] [Related]  

  • 9. In regard to Chen et Al. (Int J Radiat Oncol Biol Phys 2007;69:25-31) and Chao et Al. (Int j Radiat Oncol Biol Phys 2007;69:32-40).
    Yaeger TE
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):317; author reply 317-8. PubMed ID: 18406902
    [No Abstract]   [Full Text] [Related]  

  • 10. Erratum to: Wattson DA, Chen M-H, Moul JW, et al. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: Implications for treatment selection. Int J Radiat Oncol Biol Phys 2012;82:e773-e779.
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):730. PubMed ID: 26461024
    [No Abstract]   [Full Text] [Related]  

  • 11. Radiotherapy in pleural malignant mesothelioma: why not! In regard to Scorsetti et al. (Int J Radiat Oncol Biol Phys 2010;77:942-949); Krayenbuehl et al. (Int J Radiat Oncol Biol Phys 2010;78:628-634).
    Russi EG; Numico G; Ricardi U
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1279; author reply 1279-80. PubMed ID: 21353165
    [No Abstract]   [Full Text] [Related]  

  • 12. Erratum to: Routman DM, Funk RK, Tangsriwong K, et al. Relapse rates with surgery alone in human papillomavirus-related intermediate- and high-risk group oropharynx squamous cell cancer: A multi-institutional review. Int J Radiat Oncol Biol Phys 2017;99:938-946.
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1304. PubMed ID: 29722676
    [No Abstract]   [Full Text] [Related]  

  • 13. What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
    Nieder C
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):640-1; author reply 641. PubMed ID: 17869682
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of TGF-beta1 plasma levels: In regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2003;56: 988-995) and de Jaeger et al (Int J Radiat Oncol Biol Phys 2004;58: 1378-1387).
    Barthelemy-Brichant N
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1339; author reply 1339-40. PubMed ID: 15519811
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to "Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy" (Int J Radiat Oncol Biol Phys 2009, in press).
    Froehner M; Koch R; Litz RJ; Wirth MP
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1274. PubMed ID: 20206022
    [No Abstract]   [Full Text] [Related]  

  • 16. Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315.
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):226. PubMed ID: 30967236
    [No Abstract]   [Full Text] [Related]  

  • 17. Erratum to: Rodrigues G, Oberije C, Senan S, et al. is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small cell lung cancer beneficial? A multi-institutional propensity score matched analysis. Int J Radiat Oncol Biol Phys 2015;91:133-139.
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1115. PubMed ID: 25832709
    [No Abstract]   [Full Text] [Related]  

  • 18. Erratum to: Kirova YM, Loap P, Fourquet A. Benefit of Post Mastectomy Radiation Therapy (PMRT) in Node-Positive, HER2-Positive Patients With Breast Cancer Receiving Anti-HER2 Treatments. Int J Radiat Oncol Biol Phys 2020;106:511-513.
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):606-607. PubMed ID: 32531392
    [No Abstract]   [Full Text] [Related]  

  • 19. What is the target volume for preoperative accelerated partial breast irradiation (APBI)? In regards to Nichols et al. (Int J Radiat Oncol Biol Phys 2010;77:197-202) and Palta et al. (Int J Radiat Oncol Biol Phys 2010, in Press).
    Kim L; Shaitelman S
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):314-5; author reply 315-6. PubMed ID: 21481727
    [No Abstract]   [Full Text] [Related]  

  • 20. Erratum to: Pignol J-P, Vu TTT, Mitera G, et al. Prospective Evaluation of Severe Skin Toxicity and Pain During Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys 2015;91:157-164.
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):702. PubMed ID: 26068501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.